BMS-496
BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ) [1].
Product Specifications
CAS Number
2407854-31-1
UNSPSC
12352005
Target
DGK
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bms-496.html
Purity
99.72
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CN(C1=CC=C(Br)N=C1C(N2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)=C5[N+]([O-])=O)C5=O
Molecular Formula
C26H22BrF2N5O3
Molecular Weight
570.39
References & Citations
[1]Wichroski M, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023;15 (719) :eadh1892.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported